FARMINGDALE, N.Y., Oct. 25, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has announced their recent exhibition of the BoneScalpel™ Ultrasonic Bone Cutting System at the International Meeting on Advanced Spine Techniques which was held in Copenhagen, Denmark from July 13-16, 2011. The meeting was hosted by the Scoliosis Research Society and was attended by approximately 800 physician opinion leaders from around the world who were exposed to the latest advancements in spinal deformity surgery.
The Scoliosis Research Society continues to maintain a commitment to research and education in the field of spinal deformities. Current membership includes over 1,000 of the world's leading spine surgeons, researchers, physician assistants and orthotists who are involved in research and treatment of spinal deformities.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. It offers the convenience and speed of a power instrument while minimizing the peril associated with rotary sharps.
"We were excited about the opportunity to be part of this meeting of world leading experts in advanced spinal and spinal deformity surgery," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Our initial experience with orthopedic surgeons and neurosurgeons performing spinal deformity surgery has been very positive and the BoneScalpel has been received enthusiastically by some of the opinion leaders in the field. Adoption of the BoneScalpel technology is advancing at an accelerating rate thanks to growing clinical experience in multiple surgical specialties and the expansion of our sales channel to global coverage."About Misonix: Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com. With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.